跳至主要内容
临床试验/KCT0005627
KCT0005627进行中(未招募)未知

A Multicenter, Randomized, Active-controlled, Exploratory Clinical Trial study to evaluate the efficacy and safety of navigation guided balloon Eustachian tuboplasty for patients with chronic Eustachian tube dysfunction

Mega Medical0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 75(Year)(—)
性别
All

入选标准

  • * Subjects must meet all the following criteria.
  • (1) Male or female over the age of 19
  • (2) Chronic Eustachian tube dysfunction patients with one or more of the criteria below
  • a) Those who have three or more of the following symptoms for 12 months or longer; ear pain, ear pressure, tinnitus, cracking or popping in ears, muffled hearing, feeling that ears are clogged.
  • b) Those with otitis media with effusion whose symptoms persist even after medication.
  • c) Those with adhesive otitis media whose symptoms persist even after medication.
  • (3) Patients who voluntarily agreed in writing to participate in this clinical trial.

排除标准

  • * Subjects who meet any of the following criteria cannot participate in this study.
  • (1) Those with proved dehiscence of internal carotid artery near the Eustachian tube in computed tomography (CT) scan.
  • (2) Patients with patulous Eustachian tube.
  • (3) Patients with tympanic membrane perforation or ventilation tube insertion state.
  • (4) Patients who have Meniere’s disease or chronic sinusitis.
  • (5) Those who have anatomy that are difficult for transnasal-approach to Eustachian tube.
  • (6) Those who have history of major head or neck surgery within 4 months.
  • (7) Patients with active chronic or acute otitis media.
  • (8) Pregnant, nursing, or childbearing-age women that have plan to get pregnant during the study period.
  • (9) Those with clinically significant liver disease (ALT or AST results are more than 2.5~3 times the normal upper limit in screening test).
  • (10) Those with clinically significant kidney disease (serum Creatinine result is more than 2.0 mg/dL in screening test) or with hemodialysis.
  • (11) Those who have history of malignancy including leukemia and lymphoma within past 5 years.
  • (12) Those who have experience of other clinical trial within past 4 weeks before this study.
  • (13) In case that researcher judged that participation in this clinical trial is not appropriate.

研究者

发起方
Mega Medical

相似试验

进行中(未招募)
1 期
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's disease
EUCTR2018-004156-37-BEeuroDerm Ltd.482
进行中(未招募)
1 期
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)Parkinson's disease
EUCTR2018-004156-37-CZeuroDerm Ltd.482
招募中
3 期
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson's disease (BouNDless)Parkinson's disease
2024-511940-20-00Neuroderm Ltd.156
进行中(未招募)
1 期
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's disease
EUCTR2018-004156-37-HUeuroDerm Ltd.350
进行中(未招募)
1 期
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral treatment in subjects with Parkinson’s disease (BouNDless)MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersParkinson's disease
EUCTR2018-004156-37-GBeuroDerm Ltd.350